Your browser doesn't support javascript.
loading
Reformulating a Pharmacophore for 5-HT2A Serotonin Receptor Antagonists.
Younkin, Jason; Gaitonde, Supriya A; Ellaithy, Amr; Vekariya, Rakesh; Baki, Lia; Moreno, José L; Shah, Sneha; Drossopoulos, Peter; Hideshima, Kelsey S; Eltit, Jose Miguel; González-Maeso, Javier; Logothetis, Diomedes E; Dukat, Malgorzata; Glennon, Richard A.
Afiliação
  • Younkin J; Department of Physiology and Biophysics, School of Medicine, and ‡Department of Medicinal Chemistry, School of Pharmacy, Virginia Commonwealth University , Richmond, Virginia 23298, United States.
  • Gaitonde SA; Department of Physiology and Biophysics, School of Medicine, and ‡Department of Medicinal Chemistry, School of Pharmacy, Virginia Commonwealth University , Richmond, Virginia 23298, United States.
  • Ellaithy A; Department of Physiology and Biophysics, School of Medicine, and ‡Department of Medicinal Chemistry, School of Pharmacy, Virginia Commonwealth University , Richmond, Virginia 23298, United States.
  • Vekariya R; Department of Physiology and Biophysics, School of Medicine, and ‡Department of Medicinal Chemistry, School of Pharmacy, Virginia Commonwealth University , Richmond, Virginia 23298, United States.
  • Baki L; Department of Physiology and Biophysics, School of Medicine, and ‡Department of Medicinal Chemistry, School of Pharmacy, Virginia Commonwealth University , Richmond, Virginia 23298, United States.
  • Moreno JL; Department of Physiology and Biophysics, School of Medicine, and ‡Department of Medicinal Chemistry, School of Pharmacy, Virginia Commonwealth University , Richmond, Virginia 23298, United States.
  • Shah S; Department of Physiology and Biophysics, School of Medicine, and ‡Department of Medicinal Chemistry, School of Pharmacy, Virginia Commonwealth University , Richmond, Virginia 23298, United States.
  • Drossopoulos P; Department of Physiology and Biophysics, School of Medicine, and ‡Department of Medicinal Chemistry, School of Pharmacy, Virginia Commonwealth University , Richmond, Virginia 23298, United States.
  • Hideshima KS; Department of Physiology and Biophysics, School of Medicine, and ‡Department of Medicinal Chemistry, School of Pharmacy, Virginia Commonwealth University , Richmond, Virginia 23298, United States.
  • Eltit JM; Department of Physiology and Biophysics, School of Medicine, and ‡Department of Medicinal Chemistry, School of Pharmacy, Virginia Commonwealth University , Richmond, Virginia 23298, United States.
  • González-Maeso J; Department of Physiology and Biophysics, School of Medicine, and ‡Department of Medicinal Chemistry, School of Pharmacy, Virginia Commonwealth University , Richmond, Virginia 23298, United States.
  • Logothetis DE; Department of Physiology and Biophysics, School of Medicine, and ‡Department of Medicinal Chemistry, School of Pharmacy, Virginia Commonwealth University , Richmond, Virginia 23298, United States.
  • Dukat M; Department of Physiology and Biophysics, School of Medicine, and ‡Department of Medicinal Chemistry, School of Pharmacy, Virginia Commonwealth University , Richmond, Virginia 23298, United States.
  • Glennon RA; Department of Physiology and Biophysics, School of Medicine, and ‡Department of Medicinal Chemistry, School of Pharmacy, Virginia Commonwealth University , Richmond, Virginia 23298, United States.
ACS Chem Neurosci ; 7(9): 1292-9, 2016 09 21.
Article em En | MEDLINE | ID: mdl-27385190
ABSTRACT
Several pharmacophore models have been proposed for 5-HT2A serotonin receptor antagonists. These typically consist of two aromatic/hydrophobic moieties separated by a given distance from each other, and from a basic amine. Although specified distances might vary, the models are relatively similar in their general construction. Because our preliminary data indicated that two aromatic (hydrophobic) moieties might not be required for such action, we deconstructed the serotonin-dopamine antipsychotic agent risperidone (1) into four smaller structural fragments that were thoroughly examined in 5-HT2A receptor binding and functional (i.e., two-electrode voltage clamp (TEVC) and intracellular calcium release) assays. It was apparent that truncated risperidone analogues behaved as antagonists. In particular, 6-fluoro-3-(1-methylpiperidin-4-yl)benzisoxazole (4) displayed high affinity for 5-HT2A receptors (Ki of ca. 12 nM) relative to risperidone (Ki of ca. 5 nM) and behaved as a potent 5-HT2A serotonin receptor antagonist. These results suggest that multiple aromatic (hydrophobic) moieties are not essential for high-affinity 5-HT2A receptor binding and antagonist activity and that current pharmacophore models for such agents are very much in need of revision.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Antagonistas do Receptor 5-HT2 de Serotonina / Potenciais da Membrana Tipo de estudo: Prognostic_studies Limite: Animals / Humans Idioma: En Revista: ACS Chem Neurosci Ano de publicação: 2016 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Antagonistas do Receptor 5-HT2 de Serotonina / Potenciais da Membrana Tipo de estudo: Prognostic_studies Limite: Animals / Humans Idioma: En Revista: ACS Chem Neurosci Ano de publicação: 2016 Tipo de documento: Article